– Dr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges –

– Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future across all industries –

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive business award for audacious leaders who disrupt markets, revolutionize sectors, and have a transformational impact on lives. Over the past four decades, the program has recognized daring entrepreneurs with big ideas and bold actions that reshape our world, across all industries and sectors.

Dr. Etkin was one of nine entrepreneurs selected as a Bay Area award winner by an independent panel of judges. The winners were evaluated out of 26 finalists based on their demonstration of building long-term value through entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes. Finalists were identified from a pool of roughly 1,000 nominated candidates.

“I am honored to be named an EY Entrepreneur of the Year award winner among other esteemed entrepreneurs, CEOs, and business leaders in the Bay Area,” said Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience. “When I launched Alto out of my Stanford lab in 2019, I was motivated by a core belief in the power of industry and innovation to catalyze meaningful change for patients. This recognition is a strong testament to the broad belief in Alto's mission to make precision psychiatry a reality, our company’s progress to date, and the invaluable contributions of our entire team.”

Entrepreneur Of The Year honors many different types of business leaders for their ingenuity, courage, entrepreneurial spirit, and global impact. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future.

Regional award winners were announced on June 14, 2024, and became lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. Winners will now be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies.

About Entrepreneur Of The Year®

Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 80 countries and territories globally.

The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the World Entrepreneur Of The Year® competition. Visit ey.com/us/eoy.

About EY

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets. Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate. Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618810704/en/